BPC 157 Vascular Research: What a New Study Found
A 2026 study suggests BPC 157 may relax human arterial tissue via nitric oxide signaling. Learn what the research found and what it means for vascular health.
A newly published study in the Journal of Clinical Medicine has taken an important step toward understanding how BPC 157 may affect human blood vessels — and the findings are drawing attention from researchers and clinicians interested in the peptide's cardiovascular potential. For the first time, investigators tested BPC 157 directly on human arterial tissue, providing early mechanistic evidence that could help bridge the gap between promising animal data and real-world clinical application.
What This Study Found
The study, conducted by Yildirim, Dastan, Demeli Ertus, and colleagues and published in May 2026, examined the effects of Body Protection Compound-157 (BPC 157) on vascular tone using segments of the human internal mammary artery (IMA) — a vessel commonly used in coronary artery bypass graft (CABG) surgery. Residual IMA segments were collected from 12 patients undergoing elective CABG procedures, offering a rare and ethically sound opportunity to study peptide activity in living human tissue.
The research team divided the arterial rings into two groups: those with an intact endothelium (the inner cellular lining of blood vessels) and those that had been deliberately stripped of this lining. Both groups were first contracted using phenylephrine, a compound that causes blood vessels to tighten, and then exposed to increasing concentrations of BPC 157 (ranging from 0.01 to 1 mg/mL).
Researchers found that BPC 157 produced a concentration-dependent reduction in arterial contraction — meaning the more BPC 157 was applied, the more the vessels relaxed. Critically, this vasorelaxant effect was significantly greater in endothelium-intact rings compared to those without the endothelial lining (p < 0.05), suggesting the endothelium plays a primary role in mediating BPC 157's vascular activity.
To investigate whether nitric oxide (NO) signaling was responsible, the team pre-treated arterial rings with L-NAME, a well-established inhibitor of nitric oxide synthase (NOS) — the enzyme that produces NO. Under NOS inhibition, the contractile responsiveness of intact rings increased, and BPC 157's relaxation effect was substantially attenuated. The dose-response curves between the endothelium-intact and endothelium-denuded groups also converged at higher concentrations, suggesting that while the endothelial NO pathway is the primary driver of BPC 157's vasorelaxant effects, residual relaxation still occurred — pointing to the likelihood of additional, as-yet-uncharacterized mechanisms.
The study concludes that BPC 157 induces vasorelaxation in human arterial tissue predominantly via an endothelium-dependent nitric oxide pathway, with endothelial integrity mainly enhancing the maximum efficacy of the response.
Clinical Significance
These findings carry meaningful implications, even as the researchers themselves are careful to note that further molecular and in vivo studies are needed before clinical conclusions can be drawn.
Nitric oxide is one of the body's most important vasodilatory molecules. Produced by the endothelium, NO signals the smooth muscle of arterial walls to relax, improving blood flow and reducing vascular resistance. Impaired NO signaling is a hallmark of endothelial dysfunction, which is closely linked to hypertension, atherosclerosis, and cardiovascular disease. Any compound capable of enhancing or supporting NO-mediated vasorelaxation — particularly in human tissue — is therefore of significant scientific interest.
Prior to this study, BPC 157's vasodilatory effects had been demonstrated primarily in animal models. The peptide has also been studied for its cytoprotective, pro-angiogenic, and anti-inflammatory properties in preclinical research. However, the translation of animal findings to human physiology is never guaranteed, making this study's use of actual human arterial tissue a notable advancement in the evidence base.
The internal mammary artery is a particularly relevant vessel to study in this context. It is the conduit of choice in bypass surgery precisely because of its resilience and endothelial health. Demonstrating that BPC 157 can induce meaningful vasorelaxation in this specific artery — and that the effect is tied to endothelial NO signaling — suggests the peptide may have relevance in cardiovascular contexts where endothelial function is a key therapeutic target.
The study also raises questions about BPC 157's potential utility in conditions where endothelial dysfunction is present. The researchers noted that under NOS inhibition, BPC 157's effects diminished substantially — which implies that a healthy, functioning endothelium may be necessary to fully realize the peptide's vasorelaxant benefits. This is an important nuance that warrants further investigation.
Current Access and Compliance Context
BPC 157 is currently classified as a research compound and is not approved by the U.S. Food and Drug Administration (FDA) or equivalent regulatory bodies in most countries as a pharmaceutical drug for human use. It is not approved for the prevention, treatment, or cure of any disease or condition.
In the United States, BPC 157 has been subject to regulatory scrutiny. The FDA has taken enforcement actions regarding its compounding and distribution, and individuals seeking access to peptide therapies should be aware of the evolving regulatory landscape. The compound continues to be the subject of active preclinical and clinical research, and its legal and medical status may vary by country and jurisdiction.
The Peptide Association encourages patients and practitioners to remain informed about the regulatory status of all peptide compounds in their respective regions. Working with a qualified, licensed medical professional is essential for anyone exploring peptide-based therapies.
What Patients Should Know
If you have encountered information about BPC 157 and are curious about its potential relevance to your cardiovascular health or overall wellness, there are several important points to keep in mind.
This research is early-stage. While the 2026 study by Yildirim and colleagues represents a meaningful step forward — particularly because it used human tissue — the researchers themselves emphasize that further molecular and in vivo studies are required to clarify the clinical relevance of these findings. A controlled laboratory experiment on isolated arterial rings, while scientifically valuable, does not constitute clinical evidence of therapeutic benefit in living patients.
Animal and tissue studies do not always translate to humans. The history of pharmacology includes many compounds that showed promise in preclinical settings but did not perform as expected in clinical trials. The vascular effects observed in this study need to be replicated and expanded upon in larger, human-based studies before any clinical recommendations can be made.
Self-administration carries significant risks. BPC 157 is available through various unregulated channels, but obtaining or using research compounds outside of a supervised medical context carries unknown risks, including product quality concerns, dosing uncertainties, and potential drug interactions. The Peptide Association strongly advises against unsupervised use.
Consultation with a knowledgeable physician is critical. If you are interested in peptide research and its potential applications, speaking with a licensed medical professional who is familiar with this area of medicine is the safest and most appropriate course of action.
Conclusion
The 2026 study by Yildirim and colleagues represents a meaningful contribution to our understanding of BPC 157's vascular biology. By demonstrating concentration-dependent vasorelaxation in human internal mammary artery tissue — and linking that effect to endothelium-dependent nitric oxide signaling — the research suggests BPC 157 may have genuine relevance to cardiovascular physiology. However, the authors are clear: this is early mechanistic evidence, and significant research remains before clinical application can be considered.
As the science continues to evolve, the Peptide Association remains committed to providing evidence-based, transparent information about peptide research. If you are interested in learning more about peptide therapies and would like to connect with a qualified medical professional in your area, we encourage you to visit peptideassociation.org/find-a-doctor.
Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content presented here is based on published scientific research and should not be interpreted as an endorsement of any specific therapy, compound, or treatment protocol. BPC 157 is not approved by the FDA or comparable regulatory agencies for the treatment of any medical condition. Always consult a qualified, licensed healthcare professional before beginning any new treatment or wellness regimen. The Peptide Association does not promote or encourage the unsupervised use of any research compound.
Citation: Yildirim AK, Dastan AO, Demeli Ertus M, et al. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. Journal of Clinical Medicine. 2026;15(9):3488. doi:10.3390/jcm15093488. PMID: 42123221.
Ready to work with a peptide-specialized physician?
The Peptide Association has vetted over 160 licensed providers across the United States who specialize in peptide therapy. Find one near you or access telehealth options available in most states.